TipRanksStock Market NewsMIRM NewsMirum Pharmaceuticals (MIRM) Gets a Buy Rating from Leerink Partners

Mirum Pharmaceuticals (MIRM) Gets a Buy Rating from Leerink Partners

In a report issued on July 21, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals (MIRMResearch Report). The company’s shares closed last Wednesday at $13.95, close to its 52-week low of $13.90.

According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of -12.3% and a 39.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and Adverum Biotechnologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $47.50 average price target, a 223.0% upside from current levels. In a report issued on July 27, H.C. Wainwright also maintained a Buy rating on the stock with a $52.00 price target.

See today’s analyst top recommended stocks >>

Based on Mirum Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $50.53 million. In comparison, last year the company had a GAAP net loss of $21.31 million.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MIRM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Read More on MIRM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More